Post-mortem neurochemistry of schizophrenia

Psychological Medicine

Volumn 18, Issue 4, 1988, Pages 793-797

  Reynolds, Gavin P ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; AUTOPSY; BRAIN LEVEL; DRUG EFFECT; HUMAN; REVIEW; SCHIZOPHRENIA;

ANIMAL; AUTOPSY; BRAIN CHEMISTRY; HUMAN; SCHIZOPHRENIA;

EID: 0024108858     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291700009715     Document Type: Editorial

References (38)

1. Bacopoulos, N. G., Bustos, G., Redmond, D. E., Baulu, J. & Roth, R. H. (1978). Regional sensitivity of primate brain dopaminergic neurons to haloperidol: alterations following chronic treatment. Brain Research 157, 396–401.
2. Bacopoulos, N. G., Spokes, E. G., Bird, E. D. & Roth, R. H. (1979). Antipsychotic drug action in schizophrenic patients: effects on cortical dopamine metabolism after long-term treatment. Science 205, 1405–1407.
3. Bennett, J. P., Enna, S. J., Bylund, D. B., Gillin, J. C., Wyatt, R. J. & Snyder, S. H. (1979). Neurotransmitter receptors in frontal cortex of schizophrenics. Archives of General Psychiatry 36, 927–934.
4. Bird, E. D., Spokes, E. G. S., Barnes, J., Mackay, A. V. P., Iversen, L. L. & Shepherd, M. (1978). Glutamic acid decarboxylase in schizophrenia. Lancet ii, 156.
5. Bissette, G., Nemeroff, C. B. & Mackay, A. V. P. (1986). Peptides in schizophrenia. In Progress in Brain Research, vol. 66 (ed. P.C. Emson, M. Rossor and M. Tohyama), pp. 161–174. Elsevier: Amsterdam.
6. Bracha, H. S. (1987). Asymmetric rotational (circling) behavior, a dopamine-related asymmetry: preliminary findings in unmedicated and never-medicated schizophrenic patients. Biological Psychiatry 22, 995–1003.
7. Brown, R., Colter, N., Corsellis, J. A. N., Crow, T. J., Frith, C. D., Jagoe, R., Johnstone, E. C. & Marsh, L. (1986), Postmortem evidence of structural brain changes in schizophrenia. Archives of General Psychiatry 43, 36–42.
8. Carruthers, R., Dawbarn, D., de Quidt, M., Emson, P. C., Hunter, J. & Reynolds, G. P. (1984). Changes in the neuropeptide content of amygdala in schizophrenia. British Journal of Pharmacology 81, 190P.
9. Clow, A., Theodorou, A., Jenner, P. & Mareden, C. D. (1980). Changes in rat striatal dopamine turnover and receptor activity during one year's neuroleptic administration. European Journal of Pharmacology 63, 135–144.
10. Cross, A. J., Crow, T. J. & Owen, F. (1979). Gamma-amino-butyric acid in the brain in schizophrenia. Lancet i, 560–561.
11. Crow, T. J., Owen, F., Cross, A. J., Ferrier, I. N., Johnstone, E. C., McCreadie, R. G., Owens, D. G. C. & Poulter, M. (1981). Neurotransmitter enzymes and receptors in post-mortem brain in schizophrenia: evidence that an increase in D2 receptors is associated with the type I syndrome. In Transmitter Biochemistry of Human Brain Tissue (ed. P. Riederer and E. Usdin), pp. 85–96. Macmillan: London.
12. Czudek, C. & Reynolds, G. P. (1987). 3H-muscimol binding to post-mortem brain tissue in schizophrenia. British Journal of Pharma cology 91, 342P.
13. Emrich, H. M., Zaudig, M., Kissling, W., Dirlich, G., von Zerssen, D. & Herz, A. (1980). Des-tyrosyl-y-endorphin in schizophrenia: a double-blind trial in 13 patients. Pharmacopsychiatry 13, 290–298.
14. Farley, I. J., Price, K. S., McCullough, E., Deck, J. H. N., Hordynski, W. & Homykiewicz, O. (1978). Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain. Science 200, 456–458.
15. Ferrier, I. N., Roberts, G. W., Crow, T. J., Johnstone, E. C., Owens, D. G. C., Lee, Y. C., O'Shaughnessy, D., Adrian, T. E., Polak, J. M. & Bloom, S. R. (1983). Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sciences 33, 475–482.
16. Flor-Henry, P. (1969). Psychosis and temporal lobe epilepsy: a controlled investigation. Epilepsia 10, 363–395.
17. Hess, E. J., Bracha, H. S., Kleinman, J. E. & Creese, I. (1987). Dopamine receptor subtype imbalance in schizophrenia. Life Sciences 40, 1487–1497.
18. Homykiewicz, O. (1982). Brain catecholamines in schizophrenia - a good case for noradrenaline. Nature 299, 484–486.
19. Iversen, L. L., Reynolds, G. P. & Snyder, S. H. (1983). Pathophysiology of schizophrenia - causal role for dopamine or noradrenaline? Nature 305, 377.
20. Jacob, H. & Beckmann, H. (1986). Prenatal developmental disturbances in the limbic allocortex in schizophrenics. Journal of Neural Transmission 65, 303–326.
21. Joseph, M. H., Baker, H. F., Crow, T. J., Riley, G. J. & Risby, D. (1979). Brain tryptophan metabolism in schizophrenia: a post-mortem study of metabolism on the serotonin and kynurenine pathways in schizophrenic and control subjects. Psychopharmacology 62, 279–285.
22. Kleinman, J. E., Karoum, F., Rosenblatt, J., Gillin, J. C., Hong, J., Bridge, T. P., Zalcman, S., Storch, F., Delcarmen, R. & Wyatt, R. J. (1981). Catecholamines and peptides in post-mortem schizophrenic brains. In Biological Psychiatry 1981 (ed. C. Perris, G. Struwe and B. Jannson), pp. 711–714. Elsevier: Amsterdam.
23. Kleinman, J. E., Iadorola, M., Govoni, S., Hong, J., Gillin, J. C. & Wyatt, R. J. (1983). Post-mortem measurements of neuropeptides in human brain. Psychopharmacology Bulletin 19, 375–377.
24. Mackay, A. V. P., Iversen, L. L., Rossor, M., Spokes, E., Bird, E., Arregui, A., Creese, I. & Snyder, S. H. (1982). Increased brain dopamine and dopamine receptors in schizophrenia. Archives of General Psychiatry 31, 991–997.
25. Memo, M., Kleinman, J. E. & Hanbauer, I. (1983). Coupling of dopamine D1 recognition sites with adenylate cyclase in nuclei accumbens and caudatus of schizophrenics. Science 221, 1304–1307.
26. Owen, F., Crow, T. J., Poulter, M., Cross, A. J., Longden, A. & Riley, G. J. (1978). Increased dopamine-receptor sensitivity in schizophrenia. Lancet ii, 223–225.
27. Pimoule, C., Schoemaker, H., Reynolds, G. P. & Langer, S. Z. (1985). (3H)SCH 23390 labelled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. European Journal of Pharmacology 11, 235–237.
28. Reynolds, G. P. (1983). Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305, 527–529.
29. Reynolds, G. P. (1987). Postmortem neurochemical studies in schizophrenia. In Search for the Causes of Schizophrenia (ed. H. Haefner, W. F. Gattaz and W. Janzarik), pp. 236–240. Springer: Heidelberg.
30. Reynolds, G. P., Riederer, P., Jellinger, K. & Gabriel, E. (1981). Dopamine receptors and schizophrenia: the neuroleptic drug problem. Neuropharmacology 20, 1319–1320.
31. Reynolds, G. P., Rossor, M. N. & Iversen, L. L. (1983). Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. Journal of of Neural Transmission, Suppl. 18, 273–277.
32. Reynolds, G. P., Czudek, C., Bzowej, N. & Seeman, P. (1987). Dopamine receptor asymmetry in schizophrenia. Lancet i, 979.
33. Roberts, G. W., Ferrier, I. N., Lee, Y., Crow, T. J., Johnstone, E. C., Owens, D. G. C., Bacarese-Hamilton, A. J., McGregor, G., O'Shaughnessy, D., Polak, J. M. & Bloom, S. R. (1983). Peptides, the limbic lobe and schizophrenia. Brain Research 288, 199–211.
34. Seeman, P., Ulpian, C., Bergeron, C., Riederer, P., Jellinger, K., Gabriel, E., Reynolds, G. P. & Touriellotte, W. W. (1984). Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225, 728–731.
35. Stein, L. & Wise, C. D. (1971). Possible aetiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science 171, 1032–1036.
36. Uhl, G. R. & Kuhar, M. J. (1984). Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra. Nature 309, 350–352.
37. Whitaker, P. M., Crow, T. J. & Ferrier, I. N. (1981). Tritiated LSD binding in frontal cortex in schizophrenia. Archives of General Psychiatry 38, 278–280.
38. Wise, C. D. & Stein, L. (1973). Dopamine-β-hydroxylase deficits in the brains of schizophrenic patients. Science 181, 344–347.